Paul Campbell, who currently holds the roles of Interim Chief Financial Officer, Chief Accounting Officer, and Corporate Controller at Viatris Inc. (NASDAQ: VTRS), has completed a significant divestment of company equity. On June 25, 2026, Campbell sold 50,076 shares of Viatris common stock. The total value of this transaction reached $809,784, with the execution prices for the shares ranging between $15.979 and $16.31 per share.
This insider activity is governed by a Rule 10b5-1 trading plan that Campbell established on March 24, 2026. These pre-arranged plans allow executives to trade company stock at predetermined times, regardless of market conditions, to avoid accusations of insider trading. Following the completion of this sale, Campbell's direct ownership in Viatris stands at 316,212 shares. Additionally, he maintains an indirect stake through a 401(k) plan, which holds 318 shares of the company.
The timing of this transaction is notable given Viatris's recent market performance. The company's shares are currently trading in close proximity to their 52-week high of $17.53. This price level reflects a substantial 83% return for investors over the past year. Despite this significant appreciation, independent analysis from InvestingPro indicates that Viatris remains undervalued when compared to its Fair Value estimate. This assessment places Viatris among the promising opportunities featured on the Most Undervalued stocks list.
Financial context for this insider sale includes Viatris's recent quarterly results. The company reported strong financial performance for the first quarter of 2026, exceeding analyst expectations. Viatris achieved an adjusted earnings per share of $0.59, which surpassed the forecasted figure of $0.51. Revenue also beat estimates, coming in at $3.52 billion against an anticipated $3.35 billion.
Beyond financial metrics, Viatris is advancing its product pipeline. The U.S. Food and Drug Administration has accepted the company's New Drug Application for a fast-acting formulation of meloxicam. This non-opioid treatment is designed to address moderate-to-severe acute pain, a condition affecting over 80 million individuals in the United States annually. The FDA has established a Prescription Drug User Fee Act goal date of December 27, 2026, for the review of this application. These developments underscore Viatris's progress in both financial execution and pharmaceutical innovation.
Investors seeking deeper insights into Viatris's financial health may access additional analysis through InvestingPro, which offers eight exclusive tips and a comprehensive Pro Research Report covering this $19 billion pharmaceutical company. The combination of insider trading activity, strong earnings, and pipeline advancements presents a complex landscape for market participants evaluating Viatris's current valuation and future trajectory.